Murlentamab

• Description :

  Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) . Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming[1].

• Product Name Alternative :

  3C23K; GM102

• UNSPSC :

  12352203

• Target :

  TGF-β Receptor

• Type :

  Inhibitory Antibodies

• Related Pathways :

  TGF-beta/Smad

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/murlentamab.html

• Purity :

  95.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Murlentamab]

• Molecular Weight :

  (144.56 kDa)

• References & Citations :

  [1]Prat M, et al. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers (Basel) . 2021 Apr 13;13 (8) :1845. |[2]Barret JM, et al. The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer. Biology (Basel) . 2021 Apr 7;10 (4) :305.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [2058047-65-5]